Novasys Secures $50 Million in Series D Financing
Novasys Medical, the developer of Renessa, a non-surgical treatment for female stress urinary incontinence (SUI), secured $45 million in Series D preferred stock financing.
The round was led by Versant Ventures, with ThreeArch Partners and Skyline Ventures also participating as new investors.
Money will be used to further development and commercialization efforts of Renessa.